Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:


Last Updated: February 29, 2020

DrugPatentWatch Database Preview

CLENPIQ Drug Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

When do Clenpiq patents expire, and when can generic versions of Clenpiq launch?

Clenpiq is a drug marketed by Ferring Pharms Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twelve patent family members in nine countries.

The generic ingredient in CLENPIQ is citric acid; magnesium oxide; sodium picosulfate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

US ANDA Litigation and Generic Entry Outlook for Clenpiq

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

There is one tentative approval for the generic drug (citric acid; magnesium oxide; sodium picosulfate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for CLENPIQ
Drug Prices for CLENPIQ

See drug prices for CLENPIQ

Recent Clinical Trials for CLENPIQ

Identify potential brand extensions & 505(b)(2) entrants

Ferring PharmaceuticalsPhase 1/Phase 2

See all CLENPIQ clinical trials

Recent Litigation for CLENPIQ

Identify potential future generic entrants

District Court Litigation
Case NameDate
Ferring Pharmaceuticals Inc. v. Lupin Inc.2019-05-16

See all CLENPIQ litigation

Synonyms for CLENPIQ
Citric acid / magnesium oxide / sodium picosulfate
Citric acid mixture with magnesium oxide and sodium picosulfate
Paragraph IV (Patent) Challenges for CLENPIQ
Tradename Dosage Ingredient NDA Submissiondate
CLENPIQ SOLUTION;ORAL citric acid; magnesium oxide; sodium picosulfate 209589 2019-02-11

US Patents and Regulatory Information for CLENPIQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring Pharms Inc CLENPIQ citric acid; magnesium oxide; sodium picosulfate SOLUTION;ORAL 209589-001 Nov 28, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.